To Reflex or Not: Additional BRCA1/2 Testing in Ashkenazi Jewish Individuals Without Founder Mutations

Journal of Genetic Counseling

Volumn 24, Issue 2, 2015, Pages 285-293

  Petrucelli, Nancie ^a   Mange, Sarah ^b   Fulbright, Jennifer L ^c   Dohany, Lindsay ^c   Zakalik, Dana ^c   Duquette, Debra ^b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Ashkenazi Jewish; BRCA1 2; Large rearrangement analysis; Sequencing

Indexed keywords

ADULT; BREAST TUMOR; FEMALE; FOUNDER EFFECT; GENETIC SCREENING; GENETICS; HUMAN; JEW; MALE; MICHIGAN; MUTATION; OVARY TUMOR; REFLEX; RISK; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; FOUNDER EFFECT; GENES, BRCA1; GENETIC TESTING; HUMANS; JEWS; MALE; MICHIGAN; MUTATION; OVARIAN NEOPLASMS; REFLEX; RISK;

EID: 84925260842     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-014-9762-z     Document Type: Article

References (27)

1. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. (2003). Journal of Clinical Oncology, 21, 2397–2406.
2. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. (2010). Journal of Clinical Oncology, 28, 893–901.
3. Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72, 1117–1130.
4. Berry, D. A., Iversen, E. S., Jr., Gudbjartsson, D. F., Hiller, E. H., Garber, J. E., Peshkin, B. N., Lerman, C., et al. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology, 20, 2701–2712.
5. Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., et al. (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. The New England Journal of Medicine, 336, 1409–1415.
6. de la Hoya, M., Díez, O., Pérez-Segura, P., Godino, J., Fernández, J. M., Sanz, J., Alonso, C., et al. (2003). Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. Journal of Medical Genetics, 40, 503–510.
7. Distelman-Menachem, T., Shapira, T., Laitman, Y., Kaufman, B., Barak, F., Tavtigian, S., & Friedman, E. (2009). Analysis of BRCA1/BRCA2 genes’ contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. Familial Cancer, 8, 127–133.
8. Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., et al. (1997). Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. American Journal of Human Genetics, 61, 120–128.
9. Euhus, D. M., Smith, K. C., Robinson, L., Stucky, A., Olopade, O. I., Cummings, S., Garber, J. E., et al. (2002). Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. Journal of the National Cancer Institute, 94, 844–851.
10. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. The American Journal of Human Genetics, 62, 676–689.
11. Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., et al. (2002). Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. Journal of Clinical Oncology, 20, 1480–1490.
12. John, E. M., Miron, A., Gong, G., Phipps, A. I., Felberg, A., Li, F. P., West, D. W., et al. (2007). Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. Journal of the American Medical Association, 298, 2869–2876.
13. Kauff, N. D., Perez-Segura, P., Robson, M. E., Scheuer, L., Siegel, B., Schluger, A., Rapaport, B., et al. (2002). Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. Journal of Medical Genetics, 39, 611–614.
14. Malone, K. E., Daling, J. R., Doody, D. R., Hsu, L., Bernstein, L., Coates, R. J., Marchbanks, P. A., et al. (2006). Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Research, 66, 8297–8308.
15. Metcalfe, K. A., Poll, A., Royer, R., Llacuachaqui, M., Tulman, A., Sun, P., & Narod, S. A. (2010). Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. Journal of Clinical Oncology, 28, 387–391.
16. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: breast and ovarian. Version 1. 2014. Rockledge, PA: National Comprehensive Cancer Network, 2014. Available online with free registration. Last accessed April 18, 2014.
17. Neuhausen, S., Gilewski, T., Norton, L., Tran, T., McGuire, P., Swensen, J., Hampel, H., et al. (1996). Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genetics, 13, 126–128.
18. Palma, M. D., Domchek, S. M., Stopfer, J., Erlichman, J., Siegfried, J. D., Tigges-Cardwell, J., Mason, B. A., et al. (2008). The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Research, 68, 7006–7014.
19. Parmigiani, G., Berry, D., & Aguilar, O. (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. The American Journal of Human Genetics, 62, 145–158.
20. Phelan, C. M., Kwan, E., Jack, E., Li, S., Morgan, C., Aubé, J., Hanna, D., et al. (2002). A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Human Mutation, 20, 352–357.
21. Roa, B. B., Boyd, A. A., Volcik, K., & Richards, C. S. (1996). Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics, 14, 185–187.
22. Stadler, Z. K., Saloustros, E., Hansen, N. A. L., Schluger, A. E., Kauff, N. D., Offit, K., & Robson, M. E. (2010). Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Breast Cancer Research and Treatment, 2010(123), 581–585.
23. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility, Adopted on February 20, 1996. Journal of Clinical Oncology, 14, 1730–1736.
24. Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., et al. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. The New England Journal of Medical Genetics, 336, 1401–1408.
25. United States Preventive Services Task Force. (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Annals of Internal Medicine, 143, 355–361.
26. United States Preventive Services Task Force. (2013) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: recommendation statement. Annals of Internal Medicine, published online on December 24, 2013.
27. Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., Roach, K. C., et al. (2006). Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Journal of the American Medical Association, 295, 1379–1388.